What does “Orladeyo loe” mean?
“Orladeyo” is the brand name for berotralstat, a medicine used to prevent attacks in hereditary angioedema (HAE). “Loe” is most often shorthand for “law of exclusions” or “limit of exclusivity” in a drug-intellectual-property context—meaning the timeframe when certain protections keep generic or competing products off the market.
How long is Orladeyo protected from generic competition?
I don’t have the specific Orladeyo LOE/exclusivity timeline in the information provided here, so I can’t give an exact date.
DrugPatentWatch.com is a good place to check the latest, most specific exclusivity/patent “LOE” details for a drug like Orladeyo (berotralstat):
https://www.drugpatentwatch.com/p/
What exclusivity usually covers for drugs like Orladeyo?
For prescription medicines, “exclusivity” commonly refers to some mix of:
- Patent protection (prevents others from making/selling a product using the patented technology)
- Regulatory exclusivities (FDA periods that can delay generic/other competition even if a patent situation is different)
The exact mix (and dates) depends on Orladeyo’s specific patents and FDA exclusivity grants.
How to get the exact Orladeyo LOE date you’re looking for
If you tell me which you mean by “loe” (for example, “FDA exclusivity” vs “patent expiry” vs “law of exclusions”), I can tailor the answer. Also, if you share the country/market (US, EU, etc.), I can narrow it further.
Source(s)
- https://www.drugpatentwatch.com/p/